Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of
APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is
administered alone and concurrently with BCG.